Prosecution Insights
Last updated: May 29, 2026

Novartis Pharma AG

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
5
Non-Final OAs
0
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

6
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (6)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (67%)
1
Easy (17%)
1
Unknown (17%)

Rejection Statute Mix

BucketCases
§103 only2 (33%)
§102 only2 (33%)
§112 only1 (17%)
No statute on record1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FETTEROLF, BRANDON J 1 49.5% +14.6%
BURKETT, DANIEL JOHN 1 65.4% +24.5%
CHICKS, ASHLI ARIANA 1 64.1% +44.9%
SZNAIDMAN, MARCOS L 1 36.9% +15.9%
SCHMIDT, IZABELA MARIA 1 63.1% +53.5%
SHTERENGARTS, SAMANTHA L 1 79.4% +7.9%

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17766149 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SCHMIDT, IZABELA MARIA 264d overdue
18015856 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY CHICKS, ASHLI ARIANA 133d overdue
17925166 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF SZNAIDMAN, MARCOS L 125d overdue
18266199 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY BURKETT, DANIEL JOHN 118d overdue
18271186 OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY FETTEROLF, BRANDON J 77d overdue

Top Art Units

Art UnitApps
1626 2
1624 1
1628 1
1621 1
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18271186 OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY FETTEROLF, BRANDON J 1626 §112 Non-Final OA 77d overdue Pending Jul 06, 2023
18266199 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY BURKETT, DANIEL JOHN 1624 §102 Non-Final OA 118d overdue Pending Jun 08, 2023
18015856 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY CHICKS, ASHLI ARIANA 1626 §103 Non-Final OA 133d overdue Pending Jan 12, 2023
17925166 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF SZNAIDMAN, MARCOS L 1628 §103 Non-Final OA 125d overdue Pending Nov 14, 2022
17766149 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SCHMIDT, IZABELA MARIA 1621 Other Non-Final OA 264d overdue Pending Apr 01, 2022
17376829 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SHTERENGARTS, SAMANTHA L 1623 §102 Non-Final OA 117d overdue Pending Jul 15, 2021

Managing Novartis Pharma AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month